Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hemoglobinopathies Market

Hemoglobinopathies Market Share

Report ID: GMI11866
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Hemoglobinopathies Market Share

The industry is characterized by a highly competitive landscape, driven by rapid innovation and technological progress. Prominent pharmaceutical companies hold a significant share of the market, supported by their extensive portfolios of diagnostic tests and advanced treatment options, including a variety of medications and emerging therapeutic modalities.

Hemoglobinopathies Market Companies

Prominent players operating in the hemoglobinopathies industry include:

bluebird bio
Bristol-Myers Squibb Company
CHIESI FARMACEUTICI
Emmaus Medical
Medunik USA
Novartis
Pfizer
Prolong Pharmaceuticals
Teva Pharmaceuticals Industries
Vertex Pharmaceuticals Incorporated

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global hemoglobinopathies industry was valued at USD 6.3 billion in 2023 and is projected to grow at a 10.4% CAGR from 2024 to 2032, driven by the rising global prevalence of hemoglobin-related disorders.

The sickle cell disease segment dominated the market with USD 3.3 billion in 2023, supported by therapies such as blood transfusions, pain management drugs, and emerging treatments like gene therapy.

The North American hemoglobinopathies industry is expected to grow at a 10% CAGR, reaching USD 5.7 billion by 2032, driven by increased awareness, early diagnosis, and advanced treatment options.

Key players in the hemoglobinopathies industry include bluebird bio, Bristol-Myers Squibb Company, CHIESI FARMACEUTICI, Emmaus Medical, Medunik USA, Novartis, Pfizer, and Prolong Pharmaceuticals.